---
title: "PBPK-guided Rosuvastatin Dose Adjustments with Ticagrelor by ABCG2 Genotype in Elderly"
id: "medrxiv-19-pbpk-model-based-prediction-of-optimal-rosuvastatin-dosing-with-concomitant"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-pbpk-model-based-prediction-of-optimal-rosuvastatin-dosing-with-concomitant"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.16.26365646v1?rss=1"
published_at: "2026-10-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PBPK-guided Rosuvastatin Dose Adjustments with Ticagrelor by ABCG2 Genotype in Elderly
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-pbpk-model-based-prediction-of-optimal-rosuvastatin-dosing-with-concomitant
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.16.26365646v1?rss=1)
- **Published At:** 2026-10-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators developed physiologically based pharmacokinetic (PBPK) models for **rosuvastatin** and **ticagrelor** in PK-Sim and validated them against clinical data from healthy adults, elderly subjects, and individuals stratified by ABCG2 c.421C>A genotype. - The team optimized parameters including BCRP (ABCG2) catalytic activity and age-related declines in CYP2C9 and CYP3A4; the interaction model used competitive inhibition of BCRP by ticagrelor. - Simulations evaluated rosuvastatin steady-state exposure during ticagrelor co-administration using half and quarter standard doses; investigators applied an exposure-matching approach to identify dose adjustments that achieve comparable AUC. - Reported simulated AUC fold changes: young adults (wild-type) half-dose 1.44; young homozygous variant half-dose 0.78; elderly wild-type quarter-dose 1.06; elderly variant half-dose 1.12. - The model suggests age- and genotype-specific dosing: elderly wild-type individuals may require a larger reduction (four-fold) while elderly ABCG2 variant carriers may need only a half-dose to match exposure. - Authors cautioned the work is a preprint not peer-reviewed and stated that data are available on request; they did not report clinical safety or efficacy outcomes from prospective trials. - The study did not provide detailed clinical dosing protocols, patient-level safety data, or regulatory recommendations; investigators emphasized modelling predictions rather than clinical guidance.
## Clinical Analysis & Structured Key Points
PBPK Model-Based Prediction of Optimal Rosuvastatin Dosing with Concomitant Ticagrelor in Elderly Patients Considering ABCG2 Genetic Variant. | medRxiv Skip to main content PBPK Model-Based Prediction of Optimal Rosuvastatin Dosing with Concomitant Ticagrelor in Elderly Patients Considering ABCG2 Genetic Variant. Dat Hoang Nguyen , Hoa Thi Vinh Pham , Junje Ding , Joel Tarning doi: https://doi.org/10.64898/2026.10.16.26365646 Dat Hoang Nguyen 1 Mahidol University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hoa Thi Vinh Pham 2 Animal and Plant Quarantine Agency; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Junje Ding 3 Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: junjie{at}tropmedres.ac Joel Tarning 4 Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Aims Rosuvastatin is commonly co-administered with ticagrelor in patients with acute coronary syndrome. Ticagrelor inhibits breast cancer resistance protein (BCRP/ABCG2), increasing rosuvastatin exposure and potentially the risk of rhabdomyolysis. This risk may be further influenced by age and the ABCG2 c.421C>A variant. We aimed to predict optimal rosuvastatin dosing with ticagrelor in elderly patients stratified by ABCG2 genotype using physiologically based pharmacokinetic (PBPK) modelling Methods PBPK models for rosuvastatin and ticagrelor were developed and validated in PK-Sim using clinical data from healthy adults, elderly patients, and individuals with wild-type or homozygous ABCG2 c.421C>A genotypes. Key parameters, including BCRP catalytic activity and age-dependent declines in CYP2C9 and CYP3A4 activity, were optimized. The drug-drug interaction model incorporated competitive BCRP inhibition by ticagrelor. Rosuvastatin steady-state exposure was simulated with half or quarter standard doses during ticagrelor co-administration, and exposure matching approach was used to identify optimal dosing. Results The PBPK models demonstrated good predictive performance across populations and genotypes. In young adults with the wild-type genotype, halving the rosuvastatin dose resulted in an AUC fold change of 1.44, supporting a half-dose strategy. In young homozygous variant carriers, half-dose co-administration produced comparable exposure (AUC fold change 0.78). In elderly wild-type individuals, a four-fold dose reduction achieved comparable exposure (AUC fold change 1.06), whereas elderly variant carriers required only a half-dose reduction (1.12). Conclusions PBPK modelling supported age- and ABCG2 genotype-specific rosuvastatin dosing with ticagrelor. Elderly wild-type patients may require a further dose reduction to minimise toxicity while maintaining therapeutic exposure. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 21, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following PBPK Model-Based Prediction of Optimal Rosuvastatin Dosing with Concomitant Ticagrelor in Elderly Patients Considering ABCG2 Genetic Variant. Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share PBPK Model-Based Prediction of Optimal Rosuvastatin Dosing with Concomitant Ticagrelor in Elderly Patients Considering ABCG2 Genetic Variant. Dat Hoang Nguyen , Hoa Thi Vinh Pham , Junje Ding , Joel Tarning medRxiv 2026.10.16.26365646; doi: https://doi.org/10.64898/2026.10.16.26365646 Share This Article: Copy Citation Tools PBPK Model-Based Prediction of Optimal Rosuvastatin Dosing with Concomitant Ticagrelor in Elderly Patients Considering ABCG2 Genetic Variant. Dat Hoang Nguyen , Hoa Thi Vinh Pham , Junje Ding , Joel Tarning medRxiv 2026.10.16.26365646; doi: https://doi.org/10.64898/2026.10.16.26365646 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (632) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4939) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (670) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1665) Epidemiology (16149) Forensic Medicine (35) Gastroenterology (1234) Genetic and Genomic Medicine (7203) Geriatric Medicine (747) Health Economics (1088) Health Informatics (5215) Health Policy (1454) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16421) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (738) Neurology (7483) Nursing (375) Nutrition (1112) Obstetrics and Gynecology (1278) Occupational and Environmental Health (1028) Oncology (3707) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (491) Palliative Medicine (142) Pathology (716) Pediatrics (1844) Pharmacology and Therapeutics (748) Primary Care Research (780) Psychiatry and Clinical Psychology (6062) Public and Global Health (9907) Radiology and Imaging (2497) Rehabilitation Medicine and Physical Therapy (1498) Respiratory Medicine (1263) Rheumatology (655) Sexual and Reproductive Health (793) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [2026 ACC/AHA Dyslipidemia Guideline: Key implications for cholesterol and cardiovascular risk](https://medichelpline.com/clinical-feed/medical-news-today-0-is-your-cholesterol-too-high-per-the-new-acc-aha-guideline-5-things-to-know.md)
- [Clinicians’ Views on “Fighting the Ventilator”: Survey of ICU Practice and Gaps](https://medichelpline.com/clinical-feed/medrxiv-23-clinicians-perspectives-on-fighting-the-ventilator.md)
- [Xilio Therapeutics hires Yariv Houvras as chief medical officer](https://medichelpline.com/clinical-feed/stat-news-1-stat-up-and-down-the-ladder-the-latest-comings-and-goings.md)
- [Understanding Patient Nonadherence: The Complex Reality Behind Stopping Medications](https://medichelpline.com/clinical-feed/stat-news-3-opinion-i-thought-i-knew-why-patients-stopped-taking-their-medicine-i-was-wrong.md)
- [Cancer prevalence and characteristics in primary care patients with type 2 diabetes mellitus](https://medichelpline.com/clinical-feed/pubmed-42817592.md) (DOI: 10.1017/S1463423626101935)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.